Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APX-New1
- Development stage
- Preclinical
- Lead developer
- Aptabio Therapeutics
- Modality
- Small Molecules
01
Overview
APX-New1 is a small molecule inhibitor developed by Aptabio Therapeutics that targets the NADPH oxidase (NOX) enzyme family. It is currently being developed for the treatment of Parkinson's disease. The drug's mechanism involves the inhibition of NOX enzymes, which are key producers of reactive oxygen species (ROS) in the central nervous system. By reducing oxidative stress and subsequent neuroinflammation, APX-New1 aims to provide neuroprotective effects and slow the progression of neurodegeneration in patients with Parkinson's disease.
Beyond the preview
Go deeper on APX-New1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APX-New1.